PURPOSE: [(18) F]VM4-037 has been developed as a positron emission tomography (PET) imaging marker to detect carbonic anhydrase IX (CA-IX) overexpression and is being investigated for use as a surrogate marker for tissue hypoxia. The purpose of this study was to determine the biodistribution and estimate the radiation dose from [(18) F]VM4-037 using whole-body PET/CT scans in healthy human volunteers. PROCEDURES: Successive whole-body PET/CT scans were performed after intravenous injection of [(18) F]VM4-037 in four healthy humans. The radiotracer uptakes in different organs were determined from the analysis of the PET scans. Human radiation doses were estimated using OLINDA/EXM software. RESULTS: High uptake of [(18) F]VM4-037 was observed in the liver and kidneys, with little clearance of activity during the study period, with mean standardized uptake values of ~35 in liver and ~22 in kidneys at ~1 h after injection. The estimated effective dose was 28 ± 1 μSv/MBq and the absorbed doses for the kidneys and liver were 273 ± 31 and 240 ± 68 μGy/MBq, respectively, for the adult male phantom. Hence, the effective dose would be 10 ± 0.5 mSv for the anticipated injected activity of 370 MBq, and the kidney and liver doses would be 101 ± 11 and 89 ± 25 mGy, respectively. CONCLUSIONS: [(18) F]VM4-037 displayed very high uptake in the liver and kidneys with little clearance of activity during the study period, resulting in these organs receiving the highest radiation doses among all bodily organs. Though the effective dose and the organ doses are within the limits considered as safe, the enhanced uptake of [(18) F]VM4-037 in the kidneys and liver will make the compound unsuitable for imaging overexpression of CA-IX in those two organs. However, the tracer may be suitable for imaging overexpression of CA-IX in lesions in other regions of the body such as in the lungs or head and neck region.
PURPOSE: [(18) F]VM4-037 has been developed as a positron emission tomography (PET) imaging marker to detect carbonic anhydrase IX (CA-IX) overexpression and is being investigated for use as a surrogate marker for tissue hypoxia. The purpose of this study was to determine the biodistribution and estimate the radiation dose from [(18) F]VM4-037 using whole-body PET/CT scans in healthy human volunteers. PROCEDURES: Successive whole-body PET/CT scans were performed after intravenous injection of [(18) F]VM4-037 in four healthy humans. The radiotracer uptakes in different organs were determined from the analysis of the PET scans. Human radiation doses were estimated using OLINDA/EXM software. RESULTS: High uptake of [(18) F]VM4-037 was observed in the liver and kidneys, with little clearance of activity during the study period, with mean standardized uptake values of ~35 in liver and ~22 in kidneys at ~1 h after injection. The estimated effective dose was 28 ± 1 μSv/MBq and the absorbed doses for the kidneys and liver were 273 ± 31 and 240 ± 68 μGy/MBq, respectively, for the adult male phantom. Hence, the effective dose would be 10 ± 0.5 mSv for the anticipated injected activity of 370 MBq, and the kidney and liver doses would be 101 ± 11 and 89 ± 25 mGy, respectively. CONCLUSIONS: [(18) F]VM4-037 displayed very high uptake in the liver and kidneys with little clearance of activity during the study period, resulting in these organs receiving the highest radiation doses among all bodily organs. Though the effective dose and the organ doses are within the limits considered as safe, the enhanced uptake of [(18) F]VM4-037 in the kidneys and liver will make the compound unsuitable for imaging overexpression of CA-IX in those two organs. However, the tracer may be suitable for imaging overexpression of CA-IX in lesions in other regions of the body such as in the lungs or head and neck region.
Authors: C C Wykoff; N J Beasley; P H Watson; K J Turner; J Pastorek; A Sibtain; G D Wilson; H Turley; K L Talks; P H Maxwell; C W Pugh; P J Ratcliffe; A L Harris Journal: Cancer Res Date: 2000-12-15 Impact factor: 12.701
Authors: S Ivanov; S Y Liao; A Ivanova; A Danilkovitch-Miagkova; N Tarasova; G Weirich; M J Merrill; M A Proescholdt; E H Oldfield; J Lee; J Zavada; A Waheed; W Sly; M I Lerman; E J Stanbridge Journal: Am J Pathol Date: 2001-03 Impact factor: 4.307
Authors: S K Chia; C C Wykoff; P H Watson; C Han; R D Leek; J Pastorek; K C Gatter; P Ratcliffe; A L Harris Journal: J Clin Oncol Date: 2001-08-15 Impact factor: 44.544
Authors: M Ilie; N M Mazure; V Hofman; R E Ammadi; C Ortholan; C Bonnetaud; K Havet; N Venissac; B Mograbi; J Mouroux; J Pouysségur; P Hofman Journal: Br J Cancer Date: 2010-05-11 Impact factor: 7.640
Authors: Chaitanya R Divgi; Robert G Uzzo; Constantine Gatsonis; Roman Bartz; Silke Treutner; Jian Qin Yu; David Chen; Jorge A Carrasquillo; Steven Larson; Paul Bevan; Paul Russo Journal: J Clin Oncol Date: 2012-12-03 Impact factor: 44.544
Authors: Jean-Jacques Patard; Patricia Fergelot; Pierre I Karakiewicz; Tobias Klatte; Quoc-Dien Trinh; Nathalie Rioux-Leclercq; Jonathan W Said; Arie S Belldegrun; Allan J Pantuck Journal: Int J Cancer Date: 2008-07-15 Impact factor: 7.396
Authors: Baris Turkbey; Maria L Lindenberg; Stephen Adler; Karen A Kurdziel; Yolanda L McKinney; Juanita Weaver; Cathy D Vocke; Miriam Anver; Gennady Bratslavsky; Philip Eclarinal; Gideon Kwarteng; Frank I Lin; Nana Yaqub-Ogun; Maria J Merino; W Marston Linehan; Peter L Choyke; Adam R Metwalli Journal: Abdom Radiol (NY) Date: 2016-01
Authors: Sarah G J A Peeters; Ludwig Dubois; Natasja G Lieuwes; Dennis Laan; Martien Mooijer; Robert C Schuit; Daniela Vullo; Claudiu T Supuran; Jonas Eriksson; Albert D Windhorst; Philippe Lambin Journal: Mol Imaging Biol Date: 2015-10 Impact factor: 3.488
Authors: Xing Yang; Il Minn; Steven P Rowe; Sangeeta Ray Banerjee; Michael A Gorin; Mary Brummet; Hye Soo Lee; Soo Min Koo; Polina Sysa-Shah; Ronnie C Mease; Sridhar Nimmagadda; Mohamad E Allaf; Martin G Pomper Journal: Oncotarget Date: 2015-10-20